KAND is a severe disorder with varied life expectancy. Some individuals with milder forms may live into adulthood, while others experience rapid progression and life-threatening complications, with some reports citing a 5–7 year life expectancy for certain severe cases.

Common manifestations include intellectual disability, developmental delays, speech delays, hypotonia (decreased muscle tone), hyperreflexia (exaggerated reflexes), spastic paraplegia (weak/tight leg muscles), optic nerve atrophy (vision loss), peripheral neuropathy, and epilepsy.

KAND data is included in the RDCA-DAP® (Rare Disease Cures Accelerator-Data and Analytics Platform) to help scientists and regulatory agencies develop treatments. Get Involved:

Families and patients can participate in research through KIF1A.ORG , which hosts research networks, clinical study opportunities, and annual conferences to connect with experts. Let me know, and I can provide more targeted details. KIF1A-Associated Neurological Disorder (KAND)

Research is ongoing to understand the different mutations and their effects. A significant study at Boston Children's Hospital is analyzing EEG data to study KAND-associated epilepsy.

KAND (KIF1A-Associated Neurological Disorder) is a rare, progressive neurodegenerative disorder caused by mutations in the KIF1A gene. It is characterized by a wide spectrum of severity, often affecting motor function, vision, and cognitive development.